Roche halts development of Huntington’s disease drug tominersen after ten years of trials

Roche announced it is stopping work on tominersen, its experimental therapy for Huntington’s disease. The decision follows a Phase 2 study in which the drug performed no better than placebo.

The company also said it will discontinue an early-stage Huntington’s asset that was still in preclinical development. The move ends more than a decade of research and investment in the disease area.

Roche did not provide details on the financial impact, but the termination underscores the challenges of developing disease-modifying treatments for neurodegenerative disorders.

Analysts note that while the setback is disappointing for patients and investors, Roche retains a broader pipeline of neurology and oncology programs.